SUBSCRIBE: Print / eNewsletter
HER2 Guidelines for Breast Cancer Could Misclassify Some Patients
The ASCO-CAP guidelines for HER2 gene amplification testing leave some patients at risk for misclassification and inappropriate treatment.
Alternative Postoperative Pain Management Can Help With Addiction
Surgical oncologists can help reduce the risk of patients developing opioid dependence.
MACRA: What Oncologists Do This Year Will Affect Payments in 2019
The United States Medicare Access and CHIP Reauthorization Act of 2015 quality- and payment-related provisions took effect January 1, 2017, and how oncologists comply this year will determine their payments in 2019.
Combinations ‘Likely the Way Forward’ for Breast Cancer Immunotherapy Research
Despite breast tumors’ lower mutational loads than lung cancers and melanoma—cancers in which immunotherapy have shown particular promise—breast cancers are nevertheless immunogenic.
Breast Conservation Therapy Preferred Local Treatment Option for Stage II Disease
Breast conservation therapy is usually best for local treatment for stage II breast cancer—and biology, as well as stage, drives patient outcomes.
Including Tumor Biological Factors Improves Breast Cancer Staging
Refining the American Joint Committee on Cancer breast cancer staging system to include molecular tumor markers will improve patient risk stratification and determination of prognosis.
Can Breast Surgeons Provide Genetic Counseling?
Breast surgeons can and should provide genetic counseling to their patients because the need outstrips the availability of genetic counselors.
Challenge of Breast Reconstruction in Patients Undergoing Radiotherapy
Timing remains an important challenge for breast reconstruction in patients undergoing radiation therapy and surgery for breast cancer.
Whole-Brain Radiotherapy No ‘Magic Bullet’ for Breast Cancer CNS Metastases
Recent findings have raised doubts about the promise of whole-brain radiation therapy against metastatic brain tumors for patients with advanced breast cancer.
Does Active Surveillance Benefit Patients With Metastatic RCC?
Active surveillance prior to initiating targeted therapy might benefit patients with metastatic renal cell carcinoma, since it delays therapy and toxicities.